The estimated Net Worth of William Grossman is at least 4.19 百万$ dollars as of 16 June 2021. Mr. Grossman owns over 7,065 units of Arcus Biosciences Inc stock worth over 351,669$ and over the last 7 years he sold RCUS stock worth over 439,312$. In addition, he makes 3,400,310$ as Chief Medical Officer at Arcus Biosciences Inc.
William has made over 6 trades of the Arcus Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 7,065 units of RCUS stock worth 168,783$ on 16 June 2021.
The largest trade he's ever made was selling 7,065 units of Arcus Biosciences Inc stock on 16 June 2021 worth over 168,783$. On average, William trades about 1,146 units every 44 days since 2018. As of 16 June 2021 he still owns at least 20,723 units of Arcus Biosciences Inc stock.
You can see the complete history of Mr. Grossman stock trades at the bottom of the page.
William Grossman M.D. Ph.D. serves as Chief Medical Officer of the Company. He has over 25 years of extensive experience leading successful global clinical organizations. Dr. Grossman joined Arcus in April 2019 from Bellicum Pharmaceuticals, where he served as CMO from February 2018 to April 2019 and was responsible for Bellicum’s clinical development, regulatory affairs, clinical operations, and medical affairs organizations. Prior to Bellicum, Dr. Grossman was the Global Group Medical Director for Cancer Immunotherapy at Genentech from September 2015 to February 2018, where he led the clinical development of Tecentriq® in gastrointestinal cancers and of cancer immunotherapy combinations across all solid tumor types. Dr. Grossman designed and led the Phase 1b/2 MORPHEUS platform, a rapid and efficient paradigm for the evaluation of cancer immunotherapy combinations. Before joining Genentech, he led the development and execution of the US & global medical affairs strategy for the oncology franchise at AbbVie. Previously, Dr. Grossman served as Senior Vice President, Research & Clinical Development at Biothera, where he oversaw all discovery and clinical development efforts in oncology and immunology. Prior to joining the industry, Dr. Grossman held various positions with the Children’s Hospital of Wisconsin/Medical College of Wisconsin where he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics, and Director of the Hematology/Oncology/Bone Marrow Transplant Division for the Immunodeficiency Transplant Program. Dr. Grossman earned a B.A. in both Biology and Chemistry from the University of St. Thomas, St. Paul, (Minnesota), magna cum laude. He earned his M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine’s Medical Scientist Training Program, and completed his medical training in the Division of Pediatric Biology/Medicine at the Washington University School of Medicine.
As the Chief Medical Officer of Arcus Biosciences Inc, the total compensation of William Grossman at Arcus Biosciences Inc is 3,400,310$. There are no executives at Arcus Biosciences Inc getting paid more.
William Grossman is 50, he's been the Chief Medical Officer of Arcus Biosciences Inc since 2019. There are 10 older and 3 younger executives at Arcus Biosciences Inc. The oldest executive at Arcus Biosciences Inc is Yasunori Kaneko, 66, who is the Lead Independent Director.
William's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Arcus Biosciences Inc have traded over 12,714,957$ worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth 566,530,309$ . The most active insiders traders include Patrick Machado、Sciences, Inc. Gilead、Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of 5,400,635$. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth 20,314$.
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
Arcus Biosciences Inc executives and other stock owners filed with the SEC include: